Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC–ESI-MS/MS analysis: Application to in vivo preclinical pharmacokinetic study

Abstract

A fast HPLC–ESI-MS/MS method has been developed and validated for the quantification of the potent and selective antimigraine zolmitriptan in rat blood and cerebrospinal fluid (CSF). The assay has been then applied for in vivo preclinical studies. The analytical determination has been used to obtain pharmacokinetics of zolmitriptan in the two biological matrices after its intravenous or nasal administration. Liquid–liquid extraction of zolmitriptan was performed from 100μL rat blood samples in the presence of N6-cyclopentyladenosine (internal standard) with the employment of ethyl acetate. Calibration standards were prepared by using blood matrix and following the same liquid–liquid extraction procedure. CSF samples were analyzed without any pre-treatment steps and by using an external calibration method in pure water matrix. Chromatographic separation was performed under reversed phase and a gradient elution condition on a C18 packed column (100×2.0mm, 2.5μm particles diameter). The mobile phase was a mixture between acetonitrile, water and formic acid (0.1% v/v). The applied HPLC–MS/MS method allowed low limits of detection, as calculated from calibration curves, of 6.6 and 24.4ng/mL for water matrix and rat blood extracts, respectively. Linearity of the calibration curves was established up to 5μM (1.44μg/mL), as well as good assay accuracy. The intravenous infusion of 20μg zolmitriptan to male Sprague-Dawley rats produced blood concentrations ranging from 9.4±0.7 to 1.24±0.07μg/mL within 10h, with a terminal half-life of 3.4±0.2h. The nasal administration of a water suspension of 20μg zolmitriptan produced blood concentrations ranging from 2.92±0.21 to 0.85±0.07μg/mL within 6h. One hour after zolmitriptan intravenous infusion or nasal administration, its CSF concentrations were 0.0539±0.0016 and 0.0453±0.0012μg/mL, respectively. This study determined the suitability of the herein proposed method to investigate the pharmacokinetics of zolmitriptan after its administration by means of novel formulations and, hence, to evaluate the efficacy of innovative nose-to-brain drug delivery in preclinical studies.